¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22
±³À°ÀÏÀÚ : 2019-03-22
±³À°Àå¼Ò : ¹Ð·¹´Ï¾ö ¼­¿ï ÈúÆ°È£ÅÚ ÁöÇÏ 1Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : 2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742  
À̸ÞÀÏ : secretariat@kcnp.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø:¸éÁ¦/Á¤È¸¿ø:50,000/ºñȸ¿ø:60,000/ÁØȸ¿ø¹×±âŸ:30,000 ´çÀϵî·Ïºñ Æò»ýȸ¿ø:10,000/Á¤È¸¿ø:60,000/ºñȸ¿ø:80,000/ÁØȸ¿ø¹×±âŸ:40,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 09:30~10:30 Á¤½Å°Ç°­ÀÇÇаúÀÇ ¾ÈÀüÇÑ Áø·á ȯ°æÀ» À§ÇÑ Çö½ÇÀûÀÎ ´ëÃ¥  ÀÌ»ó¿­(¿ø±¤ÀÇ´ë) 
È޽Ġ03¿ù 22ÀÏ  10:30~10:50 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 10:50~11:15 Brain energy metabolism and vulnerability to stress  °­¿ø¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:15~11:40 Diet and physical activity impact on mood disorder  ±è¹ÎÇõ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 11:40~12:00 Brain mechanism of environmental risk for schizophrenia  °­½ÃÇö(±¹¸³Á¤½Å°Ç°­¼¾ÅÍ) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 10:50~11:15 Overview of resistant schizophrenia  ÀÌÁß¼±(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:15~11:40 Pharmacological treatment for resistant schizophrenia  ±è¼º¿Ï(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 11:40~12:00 Non-pharmacological treatment for resistant schizophrenia  ÀÌÁ¤¼®(±¹¹Î°Ç°­º¸ÇèÀϻ꺴¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:00~12:30 Treatment strategy for young patients  Á¤Á¾Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 12:30~13:00 Treatment strategy for schizophrenic patients who are intolerable to initial treatment  ¹Ú¼º¿ë(°è¿äº´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 12:00~13:00 Optimal treatment of Brintellix: Translating clinical data into practice  ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë) 
È޽Ġ03¿ù 22ÀÏ  13:00~13:20 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:20~13:45 Brexanolone iv for postpartum depression  ¿ì¿µ¼·(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 13:45~14:10 Esketamine nasal spray for depression  Á¤Çö°­(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:10~14:30 MDMA and ketamine assisted psychotherapy for PTSD  ¹ÚÁÖ¾ð(°è¿äº´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:20~13:45 Overview of resistant bipolar disorder  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 13:45~14:10 Pharmacological treatment for resistant bipolar disorder  ¼­Á¤¼®(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:10~14:30 Non-pharmacological treatment for resistant bipolar disorder  ¹®Àº¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:30~14:55 Applying personalized medicine principles to cognitive remediation (CR) for schizophrenia spectrum disorders  ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 14:55~15:20 Predictors of lithium responses in bipolar disorder  ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:20~15:40 Neuropsychological and neuroimaging markers for recurrence of major depressive disorder  °­½Â°É(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:30~14:55 Overview of resistant depression  ±è¿ø(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 14:55~15:20 Pharmacological treatment for resistant depression  ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:20~15:40 Non-pharmacological treatment for resistant depression  ÀÌ°­¼ö(Â÷ÀÇ°úÇдë) 
È޽Ġ03¿ù 22ÀÏ  15:40~15:50 È޽Ġ () 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 15:50~16:15 Etiologic controversies in adult ADHD  ¼ºÇü¸ð(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:15~16:40 Diagnostic controversies in adult ADHD  ½É¼¼ÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëA 16:40~17:00 Treatment controversies in adult ADHD  È«Á¤¿Ï(Àͻ꺴¿ø) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 15:50~16:15 Overview of resistant OCD  ³ë´ë¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:15~16:40 Pharmacological treatment for resistant OCD  ÃµÀºÁø(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 22ÀÏ ±×·£µåº¼·ëC 16:40~17:00 Non-pharmacological treatment for resistant OCD  À̽ÂÀç(°æºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãá°èÇмú´ëȸ : 2019-03-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ(Applications of Biomaterials for Corneal Diseas) : 2019-03-22
´ÙÀ½±Û 2019³â Á¦1ȸ ÆÄÁÖ½ÃÀÇ»çȸ ¿¬¼ö±³À° : 2019-03-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20530 ¼­¿ï ¿¡ÀÌÄ¡Ç÷¯½º¾çÁöº´¿ø Á¦2024-1ȸ ¿¬¼ö°­Á : 2024-05-23 0 9 2024-04-29
20529 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ : 2024-05-21 0 4 2024-04-29
20528 ¼­¿ï Á¾·Î±¸ÀÇ»çȸ ȸ¿ø¿¬¼ö±³À°(¾ß°£´¢, ´ç´¢Ä¡·á, ¹ß±âºÎÀü) : 2024-05-21 0 20 2024-04-29
20527 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦2Â÷ ¿¬¼ö±³À° : 2024-05-20 0 3 2024-04-29
20526 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ADHD ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-05-19 0 8 2024-04-29
20525 ¼­¿ï ´ëÇѽÉÆóÇ÷°ü¸¶ÃëÇÐȸ 2024 KSCTVA Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-19 0 10 2024-04-29
20524 ´ë±¸ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ´ë±¸¡¤°æºÏÁöȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 9 2024-04-29
20523 ¼­¿ï 24³âµµ ´ëÇѱâ´ÉÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 12 2024-04-29
20522 ¼­¿ï 2024³â ´ëÇѱÙÀüµµÀü±âÁø´ÜÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 6 2024-04-29
20521 ¼­¿ï ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ ¿¬¼ö°­Á : 2024-05-18 0 10 2024-04-29
20520 ¿ï»ê ¿ï»ê±¤¿ª½ÃÀÇ»çȸ Ç÷°üÀ» Á¶½ÉÇÏÀÚ : 2024-05-18 0 14 2024-04-29
20519 ¼­¿ï ´ëÇѽÉÆóÇ÷°ü¸¶ÃëÇÐȸ 2024 KSCTVA Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-18 0 5 2024-04-29
20518 ¼­¿ï Áß¾Ó´ëÇб³º´¿ø ¾È°ú ½ÉÆ÷Áö¾ö : 2024-05-18 0 17 2024-04-29
20517 ¼­¿ï ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-¼Â°³¯ : 2024-05-18 0 16 2024-04-29
20516 ¼­¿ï Á¦7ȸ °­ºÏ±¸ÀÇ»çȸ Çмú´ëȸ : 2024-05-18 0 8 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷